Supplementary Information (SI) for RSC Medicinal Chemistry. This journal is © The Royal Society of Chemistry 2024

2-(4-Bromobenzyl) tethered 4-amino aryl/alkyl-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidines: Design, Synthesis, anticancer assessment via dual topoisomerase-1/II inhibition, and *in silico* studies

Sahil Arora,^a Bhagyshree Patra,^b Isha Dhamija,^b Santosh Guru,^b Raj Kumar ^{a*}

^aLaboratory for Drug Design and Synthesis, Department of Pharmaceutical Sciences and Natural Products, School of Pharmaceutical Sciences, Central University of Punjab, Bathinda 151 401 India.

^bDepartment of Biological Sciences, National Institute of Pharmaceutical Education and Research, Hyderabad, India

*Corresponding author: Raj Kumar (raj.khunger@cup.edu.in; raj.khunger@gmail.com)

S.No.	Contents	Page No.
1.	¹ H, ¹³ C NMR and HRMS spectra's of representative compounds	S2-S8
2.	Assessment of cytotoxicity of active compounds 7a and 7r against HEK-293 cells at 10 and 25 μM concentration respectively	S9




Figure S1 ¹H NMR (d₆-DMSO, 600 MHz) of *N*-(2-aminobenzyl)-2-(4-bromobenzyl)-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-*d*]pyrimidin-4-amine (**7t**)




Figure S2 ¹H NMR (d₆-DMSO, 600 MHz) of *N*-(2-aminobenzyl)-2-(4-bromobenzyl)-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-*d*]pyrimidin-4-amine (**7t**)




Figure S3 ¹³C NMR (d₆-DMSO, 151 MHz) of *N*-(2-aminobenzyl)-2-(4-bromobenzyl)-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-4-amine (7t)




Figure S4 HRMS (ESI-TOF) of N-(2-aminobenzyl)-2-(4-bromobenzyl)-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-4-amine (7t)




Figure S5 ¹H NMR (d₆-DMSO, 600 MHz) of 2-(4-bromobenzyl)-*N*-cyclohexyl-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-*d*]pyrimidin-4-amine (7u)




Figure S6¹³C NMR (151 MHz, CDCl₃) of 2-(4-bromobenzyl)-*N*-cyclohexyl-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-4-amine (7u)




Figure S7 HRMS (ESI-TOF) of 2-(4-bromobenzyl)-N-cyclohexyl-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-4-amine (7u)




Figure S8 Assessment of cytotoxicity of active compounds 7a and 7r against HEK-293 cells at 10 and 25 μ M concentrations.